Moreover, in humans, cancer patient responding to oxaliplatin reported higher serum butyrate levels than non-responding patients, which could positively impact the regulation of CD8+ T cell immunity and facilitate chemotherapy efficacy [33]. Here, CD8A is linked to cancer.